SGLT2 inhibitors were originally developed to treat type 2 diabetes. They lower blood glucose by helping the kidneys remove more glucose through the urine.
But large clinical trials revealed something more.
People taking these medicines had fewer heart failure events, and their kidney disease progressed more slowly. Importantly, similar benefits were later found in selected people without diabetes.
So why can a diabetes medicine protect the heart and kidneys?
Their Effects Go Beyond Blood Sugar
SGLT2 inhibitors change the way the kidneys handle glucose and sodium.
By allowing more glucose and sodium to leave the body in the urine, they produce several effects at the same time. Blood glucose may fall. Blood pressure often decreases modestly. The body also loses some excess salt and fluid.
But there is another important effect: these medicines can reduce pressure within the kidney’s delicate filtering system.
Together, these changes can reduce stress on both the kidneys and the heart.
Protecting the Kidneys
The kidneys contain millions of tiny filters that continuously clean the blood.
In diabetes and chronic kidney disease, these filters can be exposed to excessive pressure. Over time, this can contribute to kidney damage and declining kidney function.
SGLT2 inhibitors help restore a healthier balance within this filtering system and reduce the pressure placed on it.
This is not just a theoretical effect.
Large clinical trials have shown that SGLT2 inhibitors can slow the progression of chronic kidney disease and reduce the risk of serious kidney complications in appropriately selected patients.
Protecting the Heart
The heart and kidneys work closely together.
When the body retains too much salt and fluid, the heart has to work harder. By helping the kidneys remove some of this excess, SGLT2 inhibitors can reduce the burden on the cardiovascular system.
Their benefits appear to involve several other processes as well, and researchers are still working to understand them fully.
What matters clinically is that large trials have shown fewer hospitalizations and episodes of worsening heart failure in patients treated with SGLT2 inhibitors.
These findings have transformed the role of this drug class in cardiovascular medicine.
Why Do They Work in People Without Diabetes?
This is one of the most interesting discoveries about SGLT2 inhibitors.
If their heart and kidney benefits came only from lowering blood glucose, we would not expect substantial benefits in people who do not have diabetes.
Yet clinical trials have demonstrated heart and kidney protection in selected patients with heart failure or chronic kidney disease, whether or not they also have diabetes.
This shows that SGLT2 inhibitors do more than control blood sugar.
But there is an important distinction.
People without diabetes are not necessarily healthy people.
Most participants without diabetes in these trials already had heart failure, chronic kidney disease or another defined medical reason for treatment. The results therefore do not show that healthy people should take these medicines for prevention or longevity.
What Does This Mean for Healthy Aging?
Heart and kidney health become increasingly important as we age.
Heart failure and chronic kidney disease can affect mobility, physical capacity, independence and survival. The two conditions are also closely connected: declining kidney function can increase cardiovascular risk, while heart disease can further impair kidney function.
Protecting these organs can therefore help preserve health for longer.
This is one reason SGLT2 inhibitors have attracted attention in longevity medicine.
For people with an appropriate medical indication, reducing serious heart and kidney complications may contribute to a longer healthspan — the years of life spent in good health and with preserved function.
Do SGLT2 Inhibitors Slow Biological Aging?
We do not yet know.
Researchers are investigating whether SGLT2 inhibitors also affect biological processes associated with aging, including inflammation, cellular energy use and oxidative stress.
These findings are interesting, but they do not yet demonstrate that SGLT2 inhibitors make people biologically younger or slow aging itself.
Their strongest evidence is much more practical: they can protect the heart and kidneys in specific groups of patients who are at increased risk.
This distinction matters.
A medicine does not have to reverse biological aging to contribute to healthier aging. Preventing or delaying diseases that lead to disability and loss of function can itself help preserve healthspan.
Based on Research
**Impact of diabetes on the effects
